Treatment of congenital thrombotic thrombocytopenic purpura with eculizumab

American Journal of Kidney Diseases

Volumn 66, Issue 6, 2015, Pages 1067-1070

  Pecoraro, Carmine ^a   Ferretti, Alfonso Vincenzo Salvatore ^a   Rurali, Erica ^b   Galbusera, Miriam ^b   Noris, Marina ^b   Remuzzi, Giuseppe ^b,c  

^a SANTOBONO PAUSILIPON CHILDREN S HOSPITAL   (Italy)

^b MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^c Azienda Ospedaliera Papa Giovanni XXIII   (Italy)

Author keywords

ADAMTS13; atypical hemolytic uremic syndrome (aHUS); complement; congenital TTP; eculizumab; terminal complement pathway; thrombotic microangiopathy (TMA); Thrombotic thrombocytopenic purpura (TTP); ultralarge vWF (ULvWF); von Willebrand factor (vWF) protease

Indexed keywords

ANTIBIOTIC AGENT; COMPLEMENT MEMBRANE ATTACK COMPLEX; CREATININE; ECULIZUMAB; HAPTOGLOBIN; HEMOGLOBIN; LACTATE DEHYDROGENASE; MENINGOCOCCUS VACCINE; VON WILLEBRAND FACTOR CLEAVING PROTEINASE; ADAM PROTEIN; ADAMTS13 PROTEIN, HUMAN; MONOCLONAL ANTIBODY;

ACUTE KIDNEY FAILURE; ANTIBIOTIC PROPHYLAXIS; ANTIBIOTIC THERAPY; ARTICLE; BLOOD SMEAR; CASE REPORT; CHILD; CREATININE BLOOD LEVEL; ENZYME IMMUNOASSAY; GLOMERULUS FILTRATION RATE; HEMODIALYSIS; HEMOGLOBIN BLOOD LEVEL; HEMOLYTIC UREMIC SYNDROME; HUMAN; LACTATE DEHYDROGENASE BLOOD LEVEL; MALE; MENINGOCOCCOSIS; PETECHIA; RELAPSE; RESPIRATORY TRACT INFECTION; SCHOOL CHILD; SINGLE DRUG DOSE; THROMBOTIC THROMBOCYTOPENIC PURPURA; TONIC CLONIC SEIZURE; TONSILLECTOMY; GENETICS; PURPURA, THROMBOTIC THROMBOCYTOPENIC; TREATMENT OUTCOME;

ADAM PROTEINS; ADAMTS13 PROTEIN; ANTIBODIES, MONOCLONAL, HUMANIZED; CHILD; HUMANS; MALE; PURPURA, THROMBOTIC THROMBOCYTOPENIC; TREATMENT OUTCOME;

EID: 84948085489     PISSN: 02726386     EISSN: 15236838     Source Type: Journal    
DOI: 10.1053/j.ajkd.2015.06.032     Document Type: Article

References (23)

1. M. Galbusera, M. Noris, and G. Remuzzi Thrombotic thrombocytopenic purpura - then and now Semin Thromb Hemost 32 2 2006 81 89
2. M. Noris, and G. Remuzzi Atypical hemolytic-uremic syndrome N Engl J Med 361 17 2009 1676 1687
3. S.R. Cataland, and H.M. Wu Diagnosis and management of complement mediated thrombotic microangiopathies Blood Rev 28 2 2014 67 74
4. H.M. Tsai Pathophysiology of thrombotic thrombocytopenic purpura Int J Hematol 91 1 2010 1 19
5. J.N. George How I treat patients with thrombotic thrombocytopenic purpura: 2010 Blood 116 20 2010 4060 4069
6. M. Scully Trends in the diagnosis and management of TTP: European perspective Transfus Apher Sci 51 1 2014 11 14
7. C.M. Legendre, C. Licht, P. Muus, and et al. Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome N Engl J Med 368 23 2013 2169 2181
8. M. Noris, F. Mescia, and G. Remuzzi STEC-HUS, atypical HUS and TTP are all diseases of complement activation Nat Rev Nephrol 8 11 2012 622 633
9. G.J. Schwartz, and D.F. Work Measurement and estimation of GFR in children and adolescents Clin J Am Soc Nephrol 4 11 2009 1832 1843
10. Agenzia Italiana del Farmaco. Pubblicazione schede di monitoraggio Registro SOLIRIS (SEUa). http://www.agenziafarmaco.gov.it/it/content/pubblicazione-schede-di-monitoraggio-registro-soliris-seua-12012015. Accessed January 12, 2015.
11. M. Noris, M. Galbusera, S. Gastoldi, and et al. Dynamics of complement activation in aHUS and how to monitor eculizumab therapy Blood 124 11 2014 1715 1726
12. M.A. Dragon-Durey, C. Loirat, S. Cloarec, and et al. Anti-factor H autoantibodies associated with atypical hemolytic uremic syndrome J Am Soc Nephrol 16 2 2005 555 563
13. R. Palla, C. Valsecchi, M. Bajetta, and et al. Evaluation of assay methods to measure plasma ADAMTS13 activity in thrombotic microangiopathies Thromb Haemost 105 2 2011 381 385
14. C. Loirat, P. Coppo, and A. Veyradier Thrombotic thrombocytopenic purpura in children Curr Opin Pediatr 25 2 2013 216 224
15. L.A. Lotta, H.M. Wu, I.J. Mackie, and et al. Residual plasmatic activity of ADAMTS13 is correlated with phenotype severity in congenital thrombotic thrombocytopenic purpura Blood 120 2 2012 440 448
16. Z.A. Hing, T. Schiller, A. Wu, and et al. Multiple in silico tools predict phenotypic manifestations in congenital thrombotic thrombocytopenic purpura Br J Haematol 160 6 2013 825 837
17. M. Reti, P. Farkas, D. Csuka, and et al. Complement activation in thrombotic thrombocytopenic purpura J Thromb Haemost 10 5 2012 791 798
18. M.P. Ruiz-Torres, F. Casiraghi, M. Galbusera, and et al. Complement activation: the missing link between ADAMTS-13 deficiency and microvascular thrombosis of thrombotic microangiopathies Thromb Haemost 93 3 2005 443 452
19. R. Tati, A.C. Kristoffersson, A.L. Stahl, and et al. Complement activation associated with ADAMTS13 deficiency in human and murine thrombotic microangiopathy J Immunol 191 5 2013 2184 2193
20. N.A. Turner, and J. Moake Assembly and activation of alternative complement components on endothelial cell-anchored ultra-large von Willebrand factor links complement and hemostasis-thrombosis PLoS One 8 3 2013 e59372
21. S. Feng, X. Liang, M.H. Kroll, D.W. Chung, and V. Afshar-Kharghan von Willebrand factor is a cofactor in complement regulation Blood 125 6 2015 1034 1037
22. J. Chapin, B. Weksler, C. Magro, and J. Laurence Eculizumab in the treatment of refractory idiopathic thrombotic thrombocytopenic purpura Br J Haematol 157 6 2012 772 774
23. E. Tsai, J. Chapin, J.C. Laurence, and H.M. Tsai Use of eculizumab in the treatment of a case of refractory, ADAMTS13-deficient thrombotic thrombocytopenic purpura: additional data and clinical follow-up Br J Haematol 162 4 2013 558 559